Table 1 Clinicopathological features of 346 NPC patients before RT

Age (years)

0.226

0.634

≤ 50

88(56.4%)

112(58.9%)

>50

68(43.6%)

78 (41.1%)

Gender

0.441

0.507

Male

119(76.3%)

139(73.2%)

Female

37(23.7%)

51(26.8%)

Pathological type

1.477

0.224

Non-keratinizing squamous cell carcinoma

148(94.8%)

185(97.4%)

Keratinizing squamous cell carcinoma

8(5.1%)

5(2.6%)

Basaloid squamous cell carcinoma

0(0.0%)

0(0.0%)

T-staging*

64.074

0.000

T1

7(4.5%)

26(13.7%)

T2

32(20.5%)

78(41.1%)

T3

50(32.1%)

71(37.4%)

T4

67(42.9%)

15(7.9%)

N-staging

4.793

0.188

N0

10(6.4%)

24(12.6%)

N1

34(21.8%)

47(24.7%)

N2

78(50.0%)

84(44.2%)

N3

34(21.8%)

35(18.4%)

M-staging

0.500

0.480

M0

144(92.3%)

179(94.2%)

M1

12(7.7%)

11(5.8%)

TNM staging*

36.008

0.000

I

1(0.6%)

5(2.6%)

II

17(10.9%)

36(18.9%)

III

44(28.2%)

95(50.0%)

IV

94(60.3%)

54(28.4%)

Smoking history

0.040

0.841

Yes

69(44.2%)

82(43.2%)

No

87(55.8%)

108(56.8%)

Intranasal medication

0.784

0.376

Yes

73(46.8%)

98(51.6%)

No

83(53.2%)

92(48.4%)

Nasal irrigation

0.857

0.355

Yes

148(94.9%)

184(96.8%)

No

8(5.1%)

6(3.2%)

Radiotherapy modality

2.609

0.106

3D-CRT

58(37.2%)

87(45.8%)

HT

98(62.8%)

103(54.2%)

Dose of primary lesions (Gy)*

4.376

0.036

≤ 70

143(91.7%)

160(84.2%)

>70

13(8.3%)

30(15.8%)

Chemotherapy modality

3.791

0.285

None

7(4.5%)

3(1.6%)

concurrent chemotherapy

15(9.6%)

25(13.2%)

Induction & concurrent chemotherapy

74(47.4%)

95(50.0%)

Induction & concurrent & adjuvant/consolidation chemotherapy

60(38.5%)

67(35.3%)

Nasal cavity/paranasal sinus invasion*

59.417

0.000

Yes

73(46.8%)

19(10.0%)

No

83(53.2%)

171(90.0%)